in this issue
Pharma/fine chemicals roundup—11 December
11:08 PM MST | December 16, 2012 | By DEEPTI RAMESH
Albemarle fine chemistry unit expands custom manufacturing facility
By Lindsay Frost
Albemarle says it has completed an expansion at its Tyrone, PA, custom manufacturing facility. The expansion, which doubles the capacity for a proprietary chemical product manufactured for an Albemarle customer, began operation last month and is now operating at its full rate. Albemarle's Fine Chemistry Services (FCS) division is a full-service provider of fine chemicals to companies across the pharmaceutical, pesticide, and specialty materials markets. “Executing this multimillion dollar expansion in less than one year allowed our customer to capitalize on the growing demand for their product, and the construction effort had no impact on fulfilling the production needs of our other customers,” says David DeCuir, director, FCS.
Pfizer completes sale of nutrition business to Nestlé; acquires NextWave
Pfizer says it has completed the previously announced sale of its nutrition business to Nestlé (Vevey, Switzerland) for $11.85 billion in cash, following the conclusion of the required regulatory process in most markets. Plans for the sale were first announced last April. In certain countries where completion will be delayed because of ongoing regulatory review, Pfizer will continue to operate the business on an interim basis. Separately, Pfizer announced that it has completed the previously announced acquisition of NextWave Pharmaceuticals (Cupertino, CA), a privately held specialty pharmaceutical company, for $700 million.
AMRI extends long term supply deal with GE Healthcare
Albany Molecular Research (AMRI; Albany, NY) says its commercial supply deal with GE Healthcare has been extended. AMRI, under the deal, will supply aminobisamide hydrochloride, an intermediate material used in diagnostic imaging agents. The new contract extends through 31 December 2016 and replaces the existing supply contract between GE and AMRI that had been in effect since 2005. Production will continue at AMRI’s large-scale manufacturing subsidiary located at Rensselaer, NY.
Indonesian Pharmacopoeia to adopt US standards
The US Pharmacopeial Convention (USP; Rockville, MD) says it has signed a letter of agreement with Indonesia’s National Agency of Drug and Food Control (NADFC) that allows NADFC to translate, copy, adapt, and incorporate materials contained in the United States Pharmacopeia and The National Formulary (USP–NF) into the Indonesian Pharmacopoeia. USP is a scientific, nonprofit organization that sets standards for the identity, strength, quality, and purity of medicines, food ingredients, and dietary supplements. USP’s drug standards are enforceable in the United States by FDA. The agreement with NADFC is valid for five years, during which the NADFC may use information published in the USP–NF and its supplements to modernize the country’s pharmacopoeia, USP says. “We will adapt the content of USP–NF to suit our local needs in order to promote access to good quality medicines in Indonesia. We recognize the USP–NF as a prime reference of science-based standards for pharmaceutical products,” says A. Retno Tyas Utami, who is part of the NADFC team responsible for publication of the Indonesian Pharmacopoeia.
Pharma exports from India to reach $25 billion by 2014
The Department of Commerce (New Delhi), part of India’s Ministry of Commerce & Industry, says that exports of generic pharmaceuticals and active pharmaceutical ingredients from India will see strong growth in the future, and that annual pharmaceutical exports from India is expected to reach $25 billion by 2014–15. “The global generics market is growing faster than the branded drugs market. The market size of drugs that lost patent protection was $270 billion in 2011 and is expected to reach $430 billion by 2016. Therefore, India will be a leading player in the generics market in the next decade,” says Rajeev Kher, additional secretary, Department of Commerce.
Morocco pharma market to grow
The pharmaceutical market in Morocco was valued at about $600 million in 2006, and is projected to reach $2.9 billion by 2020, at a compound annual growth rate of 11.1%, says a recent report by healthcare experts at GlobalData, a business intelligence provider. The economic status of Moroccans is improving because of increasing employment rates and income; consequently, citizens’ spending on healthcare services and health insurance is expected to grow, the report says. However, the GlobalData report suggests that managing the demands of elderly and poor citizens will pose a major challenge for health-care policy makers in the future.